Patent classifications
A61L17/105
BRAIDED BARBED SUTURES HAVING BARBED MONOFILAMENT INSERTS WITH CONCAVE CORE PROFILES
A braided barbed suture includes a barbed monofilament insert including an elongated core having a thickness and a plurality of barbs projecting outwardly from opposite sides of the elongated core. The braided barbed suture includes a braided sheath surrounding the elongated core to form a composite core of the braided barbed suture. The composite core has a thickness and the elongated core is located in a center of the composite core. The elongated core thickness is about 6-8 mil and the composite core thickness is about 13-18 mil. A ratio of the elongated core thickness relative to the composite core thickness is between about 0.16 to 0.91. The elongated core has transition zones that form a concave profile. The braided barbed suture has a single breaking point for both the braided sheath and the barbed monofilament insert. The barbed monofilament insert has a PDS monofilament core, and the braided sheath is a VICRYL multifilament yarn braided sheath.
POLYESTERS, POLYMER COMPOSITIONS, AND METHODS OF USING THEREOF
Provided herein are polyesters that comprise (i) monomer units derived from sugar-based bicyclic diol; (ii) monomer units derived from an unsaturated aliphatic diacid; and (iii) monomer units derived from a saturated aliphatic diacid. The monomer units derived from the ethylenically unsaturated aliphatic diacid can be present in an amount of from greater than 0 mole % to 40 mole % of the polyester. These polyesters can be formed into articles using additive manufacturing methods. The resulting articles can be biocompatible, resorbable over a span of from 3 months to 12 months following implantation in the human body, and can exhibit desirable mechanical properties for applications, including porosity and elasticity.
POLYESTERS, POLYMER COMPOSITIONS, AND METHODS OF USING THEREOF
Provided herein are polyesters that comprise (i) monomer units derived from sugar-based bicyclic diol; (ii) monomer units derived from an unsaturated aliphatic diacid; and (iii) monomer units derived from a saturated aliphatic diacid. The monomer units derived from the ethylenically unsaturated aliphatic diacid can be present in an amount of from greater than 0 mole % to 40 mole % of the polyester. These polyesters can be formed into articles using additive manufacturing methods. The resulting articles can be biocompatible, resorbable over a span of from 3 months to 12 months following implantation in the human body, and can exhibit desirable mechanical properties for applications, including porosity and elasticity.
YARNS AND FIBERS OF POLY(BUTYLENE SUCCINATE) AND COPOLYMERS THEREOF, AND METHODS OF USE THEREOF
Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.
YARNS AND FIBERS OF POLY(BUTYLENE SUCCINATE) AND COPOLYMERS THEREOF, AND METHODS OF USE THEREOF
Resorbable implants comprising poly(butylene succinate) and copolymers thereof have been developed. The implants are preferably sterilized, and contain less than 20 endotoxin units per device as determined by the limulus amebocyte lysate (LAL) assay, and are particularly suitable for use in procedures where prolonged strength retention is necessary, and can include one or more bioactive agents. The implants may be made from fibers and meshes of poly(butylene succinate) and copolymers thereof, or by 3d printing, and the fibers may be oriented. Coverings and receptacles made from forms of poly(butylene succinate) and copolymers thereof have also been developed for use with cardiac rhythm management devices and other implantable devices. These coverings and receptacles may be used to hold, or partially/fully cover, devices such as pacemakers and neurostimulators. The coverings and receptacles are made from meshes, webs, lattices, non-wovens, films, fibers, and foams, and contain antibiotics such as rifampin and minocycline.
SUTURE WITH TENSION INDICATOR
A surgical suture provides a visual indication when the suture is subjected to excessive tension. The suture has an inner core at least partially covered by a segmented outer layer. The inner core is not visible when the suture is subjected to acceptable amounts of tension, but will become visible if the suture is subjected to unacceptable amounts of tension. The visibility of the inner core thus indicates to the surgeon or similar medical professional whether or not the suture is under acceptable tension.
High Tenacity Fibers
Medical grade yarns, medical devices constructed of such yarns, and methods for making such yarns and devices are described. Polyester drawn fibers, and more particularly high strength and high tenacity micro polyester fibers for use in medical devices, and methods of preparing the same are provided.
Microfluidic extrusion
Implantable scaffolds made from biopolymer fibers. Biopolymer is dissolved in acid in a closed container made of materials inert to the acid and to the collagen to form a biopolymer solution. The solution is stirred, then centrifuged to degas it. The degassed solution is put into syringes on a holder. The number of syringes equals the number of fibers in the bundle. The syringes are mounted in a rotatable holder. Essentially equal quantities of degassed solution are extruded from the syringes to produce fibers, which are gathered and fed into a formation buffer bath. The fibers are kept taught after extrusion and dehydrated in a dehydrating solution in a dehydrating bath. The fibers are wound a collector to collect the bundle. Scaffolds then are made.
COMPOSITIONS AND METHODS FOR 3D PRINTED FIBROUS SCAFFOLDS WITH ANTIMICROBIAL PROPERTIES INCORPORATING GRAPHENE OXIDE AND POLY(E-CAPROLACTONE)
A composition of Poly(e-caprolactone)—PLC—and Graphene Oxide (GO) for use in killing bacteria that cause infections in patients implanted with medical devices, for example Staphylococcus epidermidis and Escherichia coli. Also disclosed is a method for constructing PLC/GO fibers and fibrous scaffolds by additive manufacturing and wet spinning, employing the composition and for example 3D printing. The method and compositions can be developed to produce a fibrous scaffold in which fiber diameter and PLC/GO concentrations are such that GO sheets are incorporated but at the same time exposed at the polymer surface, coffering bactericidal properties to the material, while keeping biocompatibility. Also disclosed is a fibrous PLC/GO bactericidal scaffold and the implanted medical devices having such scaffold. The composition, method, scaffold and medical devices may be used to achieve PLC/GO scaffolds and medical devices with bactericidal properties that have reduced risk of implant-associated infections.
COMPOSITIONS AND METHODS FOR 3D PRINTED FIBROUS SCAFFOLDS WITH ANTIMICROBIAL PROPERTIES INCORPORATING GRAPHENE OXIDE AND POLY(E-CAPROLACTONE)
A composition of Poly(e-caprolactone)—PLC—and Graphene Oxide (GO) for use in killing bacteria that cause infections in patients implanted with medical devices, for example Staphylococcus epidermidis and Escherichia coli. Also disclosed is a method for constructing PLC/GO fibers and fibrous scaffolds by additive manufacturing and wet spinning, employing the composition and for example 3D printing. The method and compositions can be developed to produce a fibrous scaffold in which fiber diameter and PLC/GO concentrations are such that GO sheets are incorporated but at the same time exposed at the polymer surface, coffering bactericidal properties to the material, while keeping biocompatibility. Also disclosed is a fibrous PLC/GO bactericidal scaffold and the implanted medical devices having such scaffold. The composition, method, scaffold and medical devices may be used to achieve PLC/GO scaffolds and medical devices with bactericidal properties that have reduced risk of implant-associated infections.